Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement
Status:
Recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
This study has been designed as a 12-month, open-label randomized controlled clinical trial.
The study aims to compare the efficacy and safety of three treatment strategies in IgG4-RD
patients with superficial organ involvement: Diprospan plus iguratimod, Diprospan plus
leflunomide and prednisone plus leflunomide.
Phase:
N/A
Details
Lead Sponsor:
Peking Union Medical College Hospital
Treatments:
Betamethasone Betamethasone dipropionate, betamethasone sodium phosphate drug combination Leflunomide Prednisone